Novavax ETFs To Shine Bright On Positive Vaccine Update

Medic, Hospital, Laboratory, Medical, Health, Doctor

Novavax NVAX is a formidable name on the list of companies, which are developing a COVID-19 vaccine. It recently announced very impressive updates on its protein-based COVID-19 vaccine candidate, NVX-CoV2373. The company’s vaccine candidate has delivered final efficacy of 96.4% in a pivotal Phase 3 trial in the U.K., against mild, moderate and severe diseases caused by the original COVID-19 strain.

Going on, Novavax has informed investors about the complete analysis of its Phase 2b trial taking place in South Africa. In the region, marked by a vast majority of strains that are B1.351 escape variants, the company’s coronavirus vaccine candidate delivered 55.4% efficiency among the HIV- negative trial participants. Encouragingly, both the studies conducted by the company have met statistical success parameters. Novavax is planning to submit the data for authorization to several regulatory agencies globally. Notably, the company is projecting to receive data from a 30,000-people trial in the United States and Mexico by early-April, per a Reuters article.

In this regard, Stanley C. Erck, President and Chief Executive Officer, Novavax has reportedly said, “We are very encouraged by the data showing that NVX-CoV2373 not only provided complete protection against the most severe forms of disease, but also dramatically reduced mild and moderate disease across both trials. Importantly, both studies confirmed efficacy against the variant strains.”

With regard to the coronavirus vaccine development and distribution, positive news is doing rounds. The FDA has awarded the Emergency Use Authorization to COVID-19 vaccine developed by Janssen Pharmaceutical Companies of Johnson & Johnson JNJ. The company has also informed that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended its vaccine.

Johnson & Johnson has started shipping and aims at delivering more than 20 million doses to the U.S. government in March and targets 100 million doses in the first half of 2021. Going on, Merck & Co., Inc. (MRK) has signed multiple agreements to make available its existing manufacturing facilities for the development of COVID-19 vaccines and medicines after its own efforts to create vaccines failed. It has signed a deal with Johnson & Johnson to support manufacturing of the latter’s single-shot COVID-19 vaccine.

1 2 3
View single page >> |

Disclaimer: Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.